Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis.
about
HIV infection and tropical parasitic diseases - deleterious interactions in both directions?Clinical presentation of T.b. rhodesiense sleeping sickness in second stage patients from Tanzania and UgandaShould I get screened for sleeping sickness? A qualitative study in Kasai province, Democratic Republic of CongoSafety and efficacy of the 10-day melarsoprol schedule for the treatment of second stage Rhodesiense sleeping sicknessThe death and life of the resurrection drugThe natural progression of Gambiense sleeping sickness: what is the evidence?A search for Trypanosoma brucei rhodesiense diagnostic antigens by proteomic screening and targeted cloning.Cost-effectiveness of algorithms for confirmation test of human African trypanosomiasis.Computer-aided identification of Trypanosoma brucei uridine diphosphate galactose 4'-epimerase inhibitors: toward the development of novel therapies for African sleeping sickness.Accuracy of five algorithms to diagnose gambiense human African trypanosomiasis.Sleeping sickness in travelers - do they really sleep?In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness.Parasitic infections in HIV infected individuals: diagnostic & therapeutic challengesDiscovery and verification of osteopontin and Beta-2-microglobulin as promising markers for staging human African trypanosomiasisTreatment perspectives for human African trypanosomiasis.Effective measures for controlling trypanosomiasis.Parasitic central nervous system infections in immunocompromised hosts: malaria, microsporidiosis, leishmaniasis, and African trypanosomiasis.Whole genome sequencing shows sleeping sickness relapse is due to parasite regrowth and not reinfection.Treatment options for second-stage gambiense human African trypanosomiasis.Human African trypanosomiasis: pharmacological re-engagement with a neglected disease.Overview of the effect and epidemiology of parasitic central nervous system infections in African children.Trypanosomiasis, cardiomyopathy and the risk of ischemic stroke.Drug delivery systems in the treatment of African trypanosomiasis infections.Therapy of vector-borne protozoan infections in nonendemic settings.Human African trypanosomiasis in endemic populations and travellers.Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis.Pain management in neurocritical care.Escape mechanisms of African trypanosomes: why trypanosomosis is keeping us awake.Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Médecins Sans Frontières programmes.The animal trypanosomiases and their chemotherapy: a reviewNifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Médecins Sans Frontières experience in the Democratic Republic of the Congo.Maintenance of B cells during chronic murine Trypanosoma brucei gambiense infection.Overexpression of the putative thiol conjugate transporter TbMRPA causes melarsoprol resistance in Trypanosoma brucei.African trypanosomiasis: Synthesis & SAR enabling novel drug discovery of ubiquinol mimics for trypanosome alternative oxidase.Stage determination and therapeutic decision in human African trypanosomiasis: value of polymerase chain reaction and immunoglobulin M quantification on the cerebrospinal fluid of sleeping sickness patients in Côte d'Ivoire.Future treatment options for human African trypanosomiasis.[Validity, cost and feasibility of the mAECT and CTC confirmation tests after diagnosis of African of sleeping sickness]Mortality trends and risk factors in advanced stage-2 Human African Trypanosomiasis: A critical appraisal of 23 years of experience in the Democratic Republic of Congo.Monitoring the use of nifurtimox-eflornithine combination therapy (NECT) in the treatment of second stage gambiense human African trypanosomiasisNew derivatives of bicyclic diamines with antiprotozoal activity
P2860
Q28198124-23794DA7-93C4-4E82-83C4-76EAE63C8AEAQ28477304-8D60D2A9-F296-4D78-89EF-B4559F3F9814Q28478935-59CAC644-EB93-4336-BDE2-8F4EBF19523BQ28483501-EE84EBEC-988E-461B-9341-CB40E5D6B99FQ28540609-83E44757-A823-4853-9492-247AAB7E210CQ33395342-98216998-7029-4A4E-B78D-E6718A9A5868Q33540186-D3E38945-7A64-4E1E-A6C7-6C936D803BC7Q33776699-8F161856-54F6-484E-A94B-158F9AB9E154Q33954211-F91DD387-61B5-41D0-A7E6-46824B13CE80Q33959416-FFCB483B-924C-4C35-A7A1-C24FCF616DAAQ34070616-55C48107-79E3-4B07-9BF2-803BD6AAFE77Q34500886-9E9ED059-F5E4-448F-A224-21DD1CDFDB35Q34635675-101BEAA7-9D88-409C-9759-22904D23C39CQ35006575-F1002FFE-E28A-4369-B014-658CF70435FFQ35095248-B5506FE6-C59C-4AA5-B333-4B5097890EC4Q36326229-6FEBA41A-C4FF-4D92-A40B-EF6573B1B1BCQ36328956-83417B08-33CE-4634-8C4D-7FFB1E414689Q36485648-2F132609-56BB-4786-8481-F440F82B838BQ36551049-992DEEB5-69D5-4BAC-872B-9E2BEDE04B66Q36740553-5E637EF7-3CF0-45FE-ACEF-95E03518C6C4Q37706685-D6CB42C0-76AE-48D5-9C12-38B97DF284A4Q37744965-A203B327-C975-4224-8C9E-78F919B06B38Q37876880-BC17010B-B6CD-4A6B-99CF-7A590FF7E1AEQ37879203-45C4D769-007A-478E-B7CE-A9BCDC2D811DQ37929054-09797F8E-BC0A-43CF-8075-F5AC3065C324Q37981773-8B2F5940-2600-482F-9838-E4BA60C1B8C5Q38124745-94A0E249-8840-4941-BA4E-21D5B2DC31DDQ38283759-95FA48B2-7CED-4232-B46C-0B47EFDAC67BQ38875419-9A268152-ACCF-4608-8818-28FB5E5727A9Q38975883-5D26A913-0CAE-4E5D-85DF-136F34F31260Q39223286-8053F0E1-46F2-4752-8753-4AAA0CF56ADFQ40633362-02860325-44AF-4F03-A22D-5197178AFE43Q43936767-2C7B51BA-67D1-4CE4-887F-44C6BECF5A21Q46057445-6B92C46F-6251-4758-BF47-B15479F60001Q46820909-18E408C1-400C-4899-B7C4-F39389C3455EQ48373153-ED0DD08B-31A7-4318-9ECB-003CA941FD3AQ54120045-3C47FB7A-61B6-4C36-963F-3A9C52D54D0BQ55322154-11ADE273-AABE-4426-97D9-0FD857945D02Q56504613-209EEA57-6E8E-405F-8593-537BA53A971DQ58848337-D1EBDE6C-F6C9-41AA-A055-8BB628AA1C68
P2860
Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Clinical description of enceph ...... human African trypanosomiasis.
@en
type
label
Clinical description of enceph ...... human African trypanosomiasis.
@en
prefLabel
Clinical description of enceph ...... human African trypanosomiasis.
@en
P2093
P2860
P921
P1476
Clinical description of enceph ...... human African trypanosomiasis.
@en
P2093
P2860
P304
P356
10.1046/J.1365-3156.2001.00710.X
P577
2001-05-01T00:00:00Z